Azirkitug Biosimilar - Research Grade

Human

CCR8

>1mg/ml

IgG1 - kappa

CHO Cells

Cafelkibart Biosimilar - Research Grade (ICH5420), Denikitug Biosimilar - Research Grade (ICH5474), Lanerkitug Biosimilar - Research Grade (ICH5625)

https://www.imgt.org/mAb-DB/

ICH3002

P51685

1237

Blue ice

This product is a research-grade biosimilar of azirkitug, an anti-CCR8 monoclonal antibody developed as an investigational cancer immunotherapy (also known by the code ABBV-514). It is supplied as an unconjugated, non-therapeutic analog built around the same target, CCR8 (human, UniProt P51685), and is intended strictly for research use only; it is not a clinical drug and is not for diagnostic or therapeutic application. The originator antibody was designed to engage CCR8 on tumor-infiltrating regulatory T cells, where the goal is to reprogram or deplete an immunosuppressive population within the tumor microenvironment, either alone or in combination with PD-1 pathway blockade. As a biosimilar reagent, this material recapitulates the binding specificity of the parent molecule and is useful as a reference antibody, positive control, and tool for characterizing CCR8 biology in vitro. It carries a human IgG1/kappa framework. Manufactured to research-grade specifications with low endotoxin (<1 EU/mg), it is available in bulk milligram-to-gram quantities to support assay development, screening, and comparability work. It offers a citation-supported, cost-effective alternative for laboratories studying CCR8-directed approaches. CCR8 (C-C chemokine receptor type 8) is a seven-transmembrane G protein-coupled receptor whose principal ligand is the chemokine CCL1. It was originally characterized in the context of T-helper type 2 responses, thymic development, and T-cell trafficking to the skin. In oncology, CCR8 has become a target of intense interest because it is preferentially and highly expressed on tumor-infiltrating regulatory T cells (Tregs), while being largely absent from peripheral and other tissue Tregs. These intratumoral Tregs are strongly immunosuppressive, and high CCR8 expression correlates with poor prognosis in cancers including non-small cell lung and colorectal cancer. This restricted expression pattern makes CCR8 an attractive handle for selectively targeting the suppressive Treg compartment inside tumors while sparing systemic immune regulation, motivating antibody strategies that deplete or functionally impair CCR8-positive Tregs to relieve suppression of anti-tumor immunity.

CC-CKR-8, CCR-8, CDw198, CKRL1, CMKBR8, CMKBRL2, CY6, GPRCY6, TER1, C-C motif chemokine receptor 8

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Azirkitug (anti-CCR8) Biosimilar

Q: Is the Azirkitug biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Azirkitug biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Azirkitug biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Azirkitug that binds CCR8; for research use only.